Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology is a journal indexed in SJR in Oncology with an H index of 74. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on oncology, cancer. It has an SJR impact factor of 1,549 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,549.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
1,549
H-index
74
Docs (year)
232
Docs 3y
516
Total refs
11710
Cites 3y
2067
Citable 3y
505
Cites/Doc 2y
4.07
Ref/Doc
50.47
Immediate OA
1800 €
Embargoed OA
NPD
Non OA / Submission
- €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists
View moreZoledronic acid in breast cancer: latest findings and interpretations
View moreEfficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma
View moreEditorial
View moreDoes metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy?
View moreDetection and minimally invasive treatment of early squamous lung cancer
View moreCurrent and future options in the management and treatment of uterine sarcoma
View moreCorrelation between NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and increased risk of esophageal cancer: evidence from a meta-analysis
View moreComparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
View moreCombining Notch inhibition with current therapies for breast cancer treatment
View moreClinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base
View moreClinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
View moreClinical development of S-1 for non-small cell lung cancer: a Japanese perspective
View moreA clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy
View moreCheckpoint inhibitors in lung cancer: latest developments and clinical potential
View moreCervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies
View moreCabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
View moreBlinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer
View moreBevacizumab in metastatic breast cancer: when may it be used?
View moreBalancing the efficacy and toxicity of chemotherapy in colorectal cancer
View moreAntiangiogenic therapy for refractory colorectal cancer: current options and future strategies
View moreAnaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract
View moreAdo-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
View moreAdjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review
View more